ROBOSENSE
22.12.2021 17:02:05 CET | Business Wire | Press release
RoboSense LiDAR , the leading smart LiDAR sensor provider, announced it will be exhibiting its latest cutting-edge LiDAR solutions at the Consumer Electronics Show (CES) on January 5 - 8 , 2022, starring RS-LiDAR M1 (M1), the world's first mass-produced automotive grade MEMS solid-state LiDAR. M1 will be joined at the stand by RS-Helios, the newest-generation bespoke LiDAR. RoboSense invites CES 2022 attendees to the West Hall, Tech East , Booth #6861, in Las Vegas, USA .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005289/en/
RoboSense is currently the only company in the world to have achieved mass-produced delivery of front-loading smart solid-state LiDAR. Looking ahead, RoboSense is sustainably empowered for the advent of the mass-produced LiDAR era with M1. Throughout 2021, RoboSense earned a large number of pre-installed fixed-point project orders from auto companies around the world, including the GAC Aion, WM Motor, ZEEKR (a Geely holding company), Lotus Cars, and Inceptio Technology.
M1’s extra small size makes it exceptionally convenient for front loading in mass production models. It is equipped with a unique smart "GAZE" function, which can dynamically and intelligently switch between far-field and near-field perception, substantially leveling up the performance of smart driving systems in different scenes.
This year, M1 has also been recognized for its innovation excellence and contribution to advancing smart mobility, winning a prestigious 2021 Automotive News PACE Award and a 2021 CLEPA Award from the European Association of Automotive Suppliers.
RoboSense is garnering worldwide recognition for its complete innovative portfolio in LiDAR and AI perception solutions. This is proven by its representing 10% of the global automotive pre-installed market, which ranks 1st in China and 2nd worldwide .
Taking the global stage at CES 2022, RoboSense will exhibit the latest LiDAR products and proven LiDAR technologies, including but not limited:
- RS-LiDAR-M1 , SOP version automotive-grade solid-state LiDAR
- RS-HELIOS-5515 , super-wide vertical FoV LiDAR
- RS-Bpearl , industrial unique design blind spot LiDAR
- RS-Ruby , upgraded 128-beam mechanical LiDAR
- RS-Ruby Lite , upgraded 80-beam mechanical LiDAR
- RS-Reference , full-stalk ground truth reference system
With RoboSense’s CES 2022 exhibition around the corner, all attendees - including clients, journalists, analysts, and industry partners - are welcome to visit RoboSense’s booth for detailed solution introductions and live product demonstrations. To schedule a meeting with RoboSense LiDAR and get exclusive access to news, or collaborate on upcoming stories and trends, please reach out to grace.ye@robosense.cn directly. An exciting world of smart mobility awaits.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005289/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom